Showing 121 - 140 results of 18,313 for search 'significantly ((((((less decrease) OR (we decrease))) OR (a decrease))) OR (greater decrease))', query time: 0.74s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  8. 128

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  9. 129

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134

    Col outcomes QR. by Felipe Agudelo-Hernández (20790521)

    Published 2025
    “…While students demonstrated enhanced human rights knowledge and less stigmatizing attitudes, we observed a concurrent decrease in benevolence scores.…”
  15. 135

    Pre-post comparison of study variables. by Felipe Agudelo-Hernández (20790521)

    Published 2025
    “…While students demonstrated enhanced human rights knowledge and less stigmatizing attitudes, we observed a concurrent decrease in benevolence scores.…”
  16. 136
  17. 137
  18. 138

    A Novel Type of PSMA-Targeting Ligands via β‑Branched Aromatic α‑Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity by Zong-Xiao Liu (22177765)

    Published 2025
    “…With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [<sup>68</sup>Ga]Ga-<b>PSMA-617</b>, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks. …”
  19. 139

    A Novel Type of PSMA-Targeting Ligands via β‑Branched Aromatic α‑Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity by Zong-Xiao Liu (22177765)

    Published 2025
    “…With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [<sup>68</sup>Ga]Ga-<b>PSMA-617</b>, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks. …”
  20. 140